Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by LOUIS L PISTERS and DEBORAH A KUBAN.
LOUIS L PISTERS
Connection Strength
1.596
DEBORAH A KUBAN
  1. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
    View in: PubMed
    Score: 0.177
  2. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.
    View in: PubMed
    Score: 0.153
  3. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009 Jul 01; 115(13):2872-80.
    View in: PubMed
    Score: 0.086
  4. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007 Jun; 177(6):2151-6; discussion 2156.
    View in: PubMed
    Score: 0.075
  5. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006 Aug 01; 107(3):631-9.
    View in: PubMed
    Score: 0.070
  6. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2005 Sep 01; 63(1):134-40.
    View in: PubMed
    Score: 0.066
  7. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology. 2005 Aug; 66(2):327-31.
    View in: PubMed
    Score: 0.066
  8. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer. 2005 May 15; 103(10):2060-6.
    View in: PubMed
    Score: 0.065
  9. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):993-1002.
    View in: PubMed
    Score: 0.064
  10. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jan 01; 61(1):14-9.
    View in: PubMed
    Score: 0.063
  11. Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. JAMA Netw Open. 2024 Oct 01; 7(10):e2440747.
    View in: PubMed
    Score: 0.062
  12. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc. 2004 Jul; 96(7):939-44.
    View in: PubMed
    Score: 0.061
  13. Systemic benefit of local radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1510-1; author reply 1511.
    View in: PubMed
    Score: 0.059
  14. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol. 2003 Nov; 170(5):1856-9.
    View in: PubMed
    Score: 0.058
  15. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate. J Urol. 2003 Jun; 169(6):2160-5.
    View in: PubMed
    Score: 0.057
  16. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):1-6.
    View in: PubMed
    Score: 0.056
  17. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002 Nov; 168(5):2001-5.
    View in: PubMed
    Score: 0.054
  18. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol. 2002 Aug; 168(2):536-41.
    View in: PubMed
    Score: 0.053
  19. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97.
    View in: PubMed
    Score: 0.045
  20. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76.
    View in: PubMed
    Score: 0.038
  21. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.033
  22. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8.
    View in: PubMed
    Score: 0.030
  23. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature. Clin Genitourin Cancer. 2014 Aug; 12(4):e147-50.
    View in: PubMed
    Score: 0.030
  24. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14.
    View in: PubMed
    Score: 0.025
  25. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Mar 20; 358(12):1250-61.
    View in: PubMed
    Score: 0.020
  26. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther. 2004 Apr; 11(4):273-9.
    View in: PubMed
    Score: 0.015
  27. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):755-63.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.